IP Library Granted Patent US 9,694,058
Granted Patent B2
US 9,694,058 · App. 12/446,729 · Granted Jul 4, 2017

Light-mediated anti-cell proliferative compositions and methods

Inventors: Carl F Ware (Solana Beach, CA); Timothy C. Cheung (Wollstonecraft, AU); Theresia A. Banks (San Diego, CA)
Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
A61K39/0011C07K14/70575C12N5/067C12N5/0672A61K2039/5152A61K2039/6006C12N2501/105C12N2501/11C12N2501/33C12N2503/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,058
App. No.
12/446,729
Granted
Jul 4, 2017
Kind
B2
Abstract

The tumor-necrosis factor superfamily member LIGHT (p30; TNFSF-14) is a cytokine for inducing immune responses against tumors. A novel biochemical approach is used to decorate the surface of tumor cells with LIGHT. LIGHT decorated cells can be used to vaccinate and induce effective, sustained immunity against cells expressing neo or pathogen associated antigens. Variants of LIGHT are described that enhance binding to cellular receptors (e.g., LT beta receptor) and decrease regulation by inhibitors (e.g., Decoy Receptor 3) increasing ability to stimulate immunity.

Claims (9)

1. A method of promoting, stimulating, inducing or increasing T cell immunity against a hyperproliferative cell, tumor cell, cancer cell or metastatic cell comprising administering to a subject an amount of a cell having LTbeta receptor agonist attached, conjugated or coupled to the cell membrane effective to promote, stimulate, induce or increase the subject's T cell immunity against the hyperproliferative cell, tumor cell, cancer cell or metastatic cell wherein the LTbeta receptor agonist comprises the amino acid sequence selected from any one of SEQ ID NOs:4 to 10.

2. The method of claim 1 , wherein the LTbeta receptor agonist comprises a LIGHT (p30 polypeptide) amino acid sequence with greater affinity for LTbR or HVEM as compared to native wild type LIGHT (p30 polypeptide).

3. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:4.

4. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:5.

5. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:6.

6. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:7.

7. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:8.

8. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:9.

9. The method of claim 1 , wherein the LTbeta receptor agonist comprises SEQ ID NO:10.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 29, 2010
From: LA JOLLA INSTITUTE FOR ALLERGY/IMMUNOLGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025219/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2010
From: WARE, CARL F.; BANKS, THERESIA A; CHEUNG, TIMOTHY C.
To: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
Reel/Frame 023911/0961 →
Continuity (2)
Provisional Application 60854420 · Oct 25, 2006
Related Publication 20100136061A1 · Jun 3, 2010